Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression

QR Code

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression

Kunitoshi Kamijima,1 Shinji Hashimoto,2 Eiichi Nagayoshi,2 Tsukasa Koyama3 1International University of Health and Welfare, Tochigi, 2Asahi-kasei Pharma Corporation, Tokyo, 3Ohyachi Hospital, Sapporo, Japan Background and methods: A double-blind, parallel-group, controlled study was performed to inv...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Kamijima K, Hashimoto S, Nagayoshi E, Koyama T
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2013
Sujets:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/27f580bcd7af457ea5a0eb5da9a45af0
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression [Corrigendum]
par: Kamijima K, et autres
Publié: (2013)

Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial
par: Kang RY, et autres
Publié: (2015)

Milnacipran: recent findings in depression
par: Guest editors: Stuart Montgomery (London, et autres
Publié: (2010)

Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study
par: Jean-Pierre Oli&eacute;, et autres
Publié: (2010)

Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder
par: Aoki A, et autres
Publié: (2014)

Editorial Foreword - Milnacipran: recent findings in depression
par: Stuart Montgomery, et autres
Publié: (2010)

Trazodone effects on [3H]-paroxetine and &alpha;2-adrenoreceptors in platelets of patients with major depression
par: Donatella Marazziti, et autres
Publié: (2010)

Treatment of patients with comorbid depression and diabetes with metformin and milnacipran
par: Peter Hofmann
Publié: (2010)

Effect of milnacipran on suicidality in patients with mild to moderate depressive disorder
par: Alla Avedisova, et autres
Publié: (2009)

&nbsp;Diabetes mellitus and comorbid depression: improvement of both diseases with milnacipran. A replication study (results of the Austrian Major Depression Diabetes Mellitus study group)
par: Abrahamian H, et autres
Publié: (2012)

Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study
par: Otsubo T, et autres
Publié: (2018)

Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies
par: Han Y, et autres
Publié: (2016)

Influence of serotonergic/noradrenergic gene polymorphisms on nausea and sweating induced by milnacipran in the treatment of depression
par: Hisashi Higuchi,&nbsp;Hitoshi Takahashi, et autres
Publié: (2009)

Antidepressant therapy with milnacipran and venlafaxine
par: Lucilla Mansuy
Publié: (2010)

Milnacipran: a unique antidepressant?
par: Siegfried Kasper, et autres
Publié: (2010)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
par: Huang J, et autres
Publié: (2018)

Sex differences in the prediction of the effectiveness of paroxetine for patients with major depressive disorder identified using a receiver operating characteristic curve analysis for early response [Corrigendum]
par: Tomita T, et autres
Publié: (2014)

A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD
par: A. Castrioto, et autres
Publié: (2020)

Effect of triiodothyronine (T3) augmentation of acute milnacipran administration on monoamine levels: an in vivo microdialysis study in rats
par: Kitaichi Y, et autres
Publié: (2012)

Role and rationale for the use of milnacipran in the management of fibromyalgia
par: Jay D Kranzler, et autres
Publié: (2010)

Usefulness of milnacipran in treating phantom limb pain
par: Matsumoto Y, et autres
Publié: (2012)

Differential clinical effects of fluvoxamine by the effect of age in Japanese female major depressive patients
par: Hisashi Higuchi, et autres
Publié: (2009)

Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial
par: Howard E. Gendelman, et autres
Publié: (2017)

The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients
par: Koshino Y, et autres
Publié: (2013)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
par: Kishi T, et autres
Publié: (2017)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
par: Mazen K Ali, et autres
Publié: (2011)

Improvement of the noradrenergic symptom cluster following treatment with milnacipran
par: Kasper S, et autres
Publié: (2011)

Suicidality: risk factors and the effects of antidepressants. The example of parallel reduction of suicidality and other depressive symptoms during treatment with the SNRI, milnacipran
par: Philippe Courtet
Publié: (2010)

Rapid improvement of depressive symptoms in suicide attempters following treatment with milnacipran and tricyclic antidepressants &ndash; a case series
par: Kirino E, et autres
Publié: (2011)

Optimized regimens of combined medications for the treatment of major depressive disorder: a double-blind, randomized-controlled trial
par: Zuilhof Z, et autres
Publié: (2018)

Oxybutynin reduces sweating in depressed patients treated with sertraline: a double-blind, placebo-controlled, clinical study
par: Ghaleiha A, et autres
Publié: (2012)

A role of Yueju in fast-onset antidepressant action on major depressive disorder and serum BDNF expression: a randomly double-blind, fluoxetine-adjunct, placebo-controlled, pilot clinical study
par: Wu R, et autres
Publié: (2015)

Predisposition for borderline personality disorder with comorbid major depression is associated with that for polycystic ovary syndrome in female Japanese population
par: Kawamura S,&nbsp;Maesawa C,&nbsp;Nakamura K,&nbsp;Nakayama K,&nbsp;Morita M,&nbsp;Hiruma Y,&nbsp;Yoshida T,&nbsp;Sakai A,&nbsp;Masuda T
Publié: (2011)

Safety and effectiveness of controlled-release paroxetine in routine clinical practice: results of a postmarketing surveillance study of patients with depression
par: Kato M, et autres
Publié: (2015)

Rosa damascena oil improves SSRI-induced sexual dysfunction in male patients suffering from major depressive disorders: results from a double-blind, randomized, and placebo-controlled clinical trial
par: Farnia V, et autres
Publié: (2015)

Efficacy and safety of generic escitalopram (Lexacure®) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study
par: Jeong JH, et autres
Publié: (2015)

Effects of milnacipran on binge eating &ndash; a pilot study
par: Shun&rsquo;ichi Noma, et autres
Publié: (2008)

Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group)
par: Heidemarie Abrahamian, et autres
Publié: (2009)

Efficacy of atropine combined with paroxetine in vagus nerve excitatory panic disorder
par: Du N, et autres
Publié: (2015)

Combined application of eicosapentaenoic acid and docosahexaenoic acid on depression in women: a meta-analysis of double-blind randomized controlled trials
par: Yang JR, et autres
Publié: (2015)